Jump to content

ChromaDex

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by WikiCleanerBot (talk | contribs) at 14:16, 26 February 2023 (v2.05b - Bot T20 CW#61 - Fix errors for CW project (Reference before punctuation)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

ChromaDex, Inc
Company typePublic
Nasdaq: CDXC
Russell 2000 Index component
IndustryDietary supplements, food ingredients, chemical sample analysis
Founded1999
HeadquartersLos Angeles, California, United States
Key people
Rob Fried
(CEO)
Frank Jaksch
(Co-Founder, Executive Chairman)
ProductsTru Niagen
Websitewww.chromadex.com

ChromaDex is a dietary supplement and food ingredient company based in Los Angeles, California founded in 1999 that is publicly traded on the NASDAQ.

In 2011, ChromaDex licensed patents from Dartmouth College, Cornell University, and Washington University in St. Louis regarding nicotinamide riboside, which it markets and sells as an ingredient under the brand name Niagen and sells directly to consumers as Tru Niagen.[1] ChromaDex licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound under the brand name pTeroPure.[2] ChromaDex no longer sells pTeroPure.[3]

ChromaDex also licensed patents from the University of Mississippi on Immulina, a proprietary extract of Arthrospira platensis (or spirulina, a type of algae) which it continues to sell today as an ingredient for use in dietary supplements.

History

Founded in 1999 by Frank Jaksch, ChromaDex first acquired licensed Dartmouth patents on nicotinamide riboside in 2012, leading to the commercialization of Niagen in 2013.  

ChromaDex is traded on the NASDAQ (as CDXC) as of April 2016 and was added to the U.S. Small Cap Russell 2000 Index in June 2018.  

In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone nicotinamide riboside supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million, led by Horizons Ventures, the investment firm of Hong Kong billionaire Li Ka-Shing, as well as venture capitalists and strategic investors, including ICONIQ Capital, to support research and development, and global expansion.  

Niagen clinical studies

Niagen, the active ingredient in Tru Niagen, is the only patented form of nicotinamide riboside that has been extensively studied in published human clinical trials.[4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]

Thirteen peer-reviewed clinical studies using Niagen have been published in high-tiered biomedical journals, demonstrating an increase in NAD+*.[4][5][6][7][8][9][10][11][12][13][21][22][24] These 13 clinical studies include the first clinical trials supporting the bioavailability, safety, efficacy, pharmacokinetics, dose-response effect on blood NAD+ levels in humans, as well as its health benefits, including improvements in cardiovascular health, liver health, body composition, and mitochondrial function.  

Additional studies in humans are ongoing or have recently completed (as of December 2022). More specifically, an additional 40+ completed or ongoing clinical trials investigating nicotinamide riboside only are currently registered on www.clinicaltrials.gov.  

Research initiatives

The ChromaDex External Research Program (CERP TM) is setting the industry standard for excellence in collaborative research on NAD+. Through CERP , ChromaDex partners with independent,third-party leading universities and research institutions worldwide and upon request, donates Niagen, one of the most studied and efficient modern NAD+ precursors in the healthy aging space, and other materials in bulk, via material transfer agreements (MTAs) to uncover the full potential of NAD+.  

CERP is leading the industry in promoting and supporting NAD+ research. CERP doesn’t limit material donations to studies that will demonstrate a business benefit to ChromaDex, and supports research outside of the framework for dietary supplements. Research through CERP is primarily independently driven, and ChromaDex only provides protocol recommendations, based upon non-public expertise, to improve the likelihood of success. ChromaDex does not alter or influence data analysis, data interpretation, or publication rights.  

In addition to receiving material donations thoroughly tested by the ChromaDex QA & QC teams via MTA for research, these investigators receive additional benefits through CERP including receiving technical support to help improve the likelihood of success of their research, and MTA language that encourages the investigator and institution to develop and own intellectual property.

CERP has proven to be beneficial to all researchers and product developers in the NAD+ space, including direct competitors, but research from the program has demonstrated that NAD+ supplementation promotes cellular health and may be beneficial to vulnerable health populations. Recent clinical research advances through CERP have demonstrated significantly lower NAD+ levels in age-related conditions including heart disease, Parkinson’s disease, ataxia telangiectasia (AT), autoimmune disorders, and others, while demonstrating NAD-boosting benefits following supplementation with Niagen. This body of research is still growing, and further investigation is needed to determine to what extent Niagen supplementation affects these health outcomes.  

In January 2022, CERP celebrated its 100th published peer-reviewed study on the company’s flagship ingredient Niagen and other materials.  

In Apri 2022, ChromaDex announced the achievement of its 250th external research agreement.

Partnerships and joint ventures

In June 2022, ChromaDex signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen into mainland China, and in November 2022 the company announced an agreement to launch a joint venture (JV) in the same territory. China’s marketplace can benefit greatly from Tru Niagen, with more than 260 million people over the age of 60.  

A new partnership with MyPharma2Go was formed to conduct cross-border sales of Tru Niagen in Brazil—the first Latin American country to welcome the brand.  

ChromaDex announced a new supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs).  

ChromaDex and Nestlé Health Science announced a new Niagen commercial supply agreement and $5 million investment.

In 2022, ChromaDex launched a Tru Niagen partnership with ShopHQ, a multiplatform interactive television network with live TV programming that reaches roughly 90 million U.S. homes, and influencer Danny Seo, an authoritative voice on living a healthy, natural, good-for-you life.

In 2022, ChromaDex partnered with Juvenis for cross-border sales of Tru Niagen into South Korea.

In 2018, ChromaDex announced a Tru Niagen partnership with Watsons, the leading health and beauty retailer in Asia and Europe.  

In 2021, Tru Niagen launched in 3,800 Walmart stores across the United States.  

In 2021, ChromaDex and Health & Happiness (H&H) Group announced a supply agreement for Niagen, in which H&H Group expanded the Swisse® healthy aging product line into the growing NAD+ space with Niagen.  

Awards

NutraIngredients, a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERP) with a 2022 European NutraIngredients Award in the “Nutrition Research Project” category for developing the science behind patented Niagen. In 2019, NutraIngredients awarded Tru Niagen the Ingredient of the Year award in the Healthy Aging category.

Tru Niagen is one of Amazon U.S.’s top-selling brands in the vitamin B3 category for boosting NAD+ levels as of December 2022.  

References

  1. ^ Weintraub, Karen. "The Life Extension Death Match". NEO.LIFE.
  2. ^ Neeb, Matthew (2011-06-20). "Ole Miss grants exclusive patent rights to ChromaDex Corp". The Daily Mississippian. Archived from the original on 2012-04-18. Retrieved 2012-05-25.
  3. ^ Krawiec, Sebastian (2018-10-31). "ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol". Nutritional Outlook. Retrieved 2020-05-01.
  4. ^ a b Trammell, Samuel A. J.; Schmidt, Mark S.; Weidemann, Benjamin J.; Redpath, Philip; Jaksch, Frank; Dellinger, Ryan W.; Li, Zhonggang; Abel, E. Dale; Migaud, Marie E.; Brenner, Charles (2016-10-10). "Nicotinamide riboside is uniquely and orally bioavailable in mice and humans". Nature Communications. 7 (1): 12948. doi:10.1038/ncomms12948. ISSN 2041-1723. PMC 5062546. PMID 27721479.
  5. ^ a b Airhart, Sophia E.; Shireman, Laura M.; Risler, Linda J.; Anderson, Gail D.; Gowda, G. A. Nagana; Raftery, Daniel; Tian, Rong; Shen, Danny D.; O’Brien, Kevin D. (2017-12-06). "An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers". PLOS ONE. 12 (12): e0186459. doi:10.1371/journal.pone.0186459. ISSN 1932-6203. PMC 5718430. PMID 29211728.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  6. ^ a b Martens, Christopher R.; Denman, Blair A.; Mazzo, Melissa R.; Armstrong, Michael L.; Reisdorph, Nichole; McQueen, Matthew B.; Chonchol, Michel; Seals, Douglas R. (2018-03-29). "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults". Nature Communications. 9 (1): 1286. doi:10.1038/s41467-018-03421-7. ISSN 2041-1723. PMC 5876407. PMID 29599478.
  7. ^ a b Dollerup, Ole L; Christensen, Britt; Svart, Mads; Schmidt, Mark S; Sulek, Karolina; Ringgaard, Steffen; Stødkilde-Jørgensen, Hans; Møller, Niels; Brenner, Charles; Treebak, Jonas T; Jessen, Niels (2018-08-01). "A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects". The American Journal of Clinical Nutrition. 108 (2): 343–353. doi:10.1093/ajcn/nqy132. ISSN 0002-9165.
  8. ^ a b Conze, Dietrich; Brenner, Charles; Kruger, Claire L. (2019-07-05). "Safety and Metabolism of Long-term Administration of Niagen (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults". Scientific Reports. 9 (1): 9772. doi:10.1038/s41598-019-46120-z. ISSN 2045-2322. PMC 6611812. PMID 31278280.
  9. ^ a b Elhassan, Yasir S.; Kluckova, Katarina; Fletcher, Rachel S.; Schmidt, Mark S.; Garten, Antje; Doig, Craig L.; Cartwright, David M.; Oakey, Lucy; Burley, Claire V.; Jenkinson, Ned; Wilson, Martin; Lucas, Samuel J. E.; Akerman, Ildem; Seabright, Alex; Lai, Yu-Chiang (2019-08-13). "Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures". Cell Reports. 28 (7): 1717–1728.e6. doi:10.1016/j.celrep.2019.07.043. ISSN 2211-1247. PMC 6702140. PMID 31412242.
  10. ^ a b Dollerup, Ole L; Trammell, Samuel A J; Hartmann, Bolette; Holst, Jens J; Christensen, Britt; Møller, Niels; Gillum, Matthew P; Treebak, Jonas T; Jessen, Niels (2019-11-01). "Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity". The Journal of Clinical Endocrinology & Metabolism. 104 (11): 5703–5714. doi:10.1210/jc.2019-01081. ISSN 0021-972X.
  11. ^ a b Dollerup, Ole L.; Chubanava, Sabina; Agerholm, Marianne; Søndergård, Stine D.; Altıntaş, Ali; Møller, Andreas B.; Høyer, Kasper F.; Ringgaard, Steffen; Stødkilde‐Jørgensen, Hans; Lavery, Gareth G.; Barrès, Romain; Larsen, Steen; Prats, Clara; Jessen, Niels; Treebak, Jonas T. "Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin‐resistant men". The Journal of Physiology. 598 (4): 731–754. doi:10.1113/JP278752. ISSN 0022-3751.
  12. ^ a b Remie, Carlijn ME; Roumans, Kay HM; Moonen, Michiel PB; Connell, Niels J; Havekes, Bas; Mevenkamp, Julian; Lindeboom, Lucas; de Wit, Vera HW; van de Weijer, Tineke; Aarts, Suzanne ABM; Lutgens, Esther; Schomakers, Bauke V; Elfrink, Hyung L; Zapata-Pérez, Rubén; Houtkooper, Riekelt H (2020-08-01). "Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans". The American Journal of Clinical Nutrition. 112 (2): 413–426. doi:10.1093/ajcn/nqaa072. ISSN 0002-9165. PMC 7398770. PMID 32320006.
  13. ^ a b Zhang, Cheng; Bjornson, Elias; Arif, Muhammad; Tebani, Abdellah; Lovric, Alen; Benfeitas, Rui; Ozcan, Mehmet; Juszczak, Kajetan; Kim, Woonghee; Kim, Jung Tae; Bidkhori, Gholamreza; Ståhlman, Marcus; Bergh, Per‐Olof; Adiels, Martin; Turkez, Hasan. "The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease". Molecular Systems Biology. 16 (4). doi:10.15252/msb.209495. ISSN 1744-4292. PMC 7184219. PMID 32337855.
  14. ^ Zhou, Bo; Wang, Dennis Ding-Hwa; Qiu, Yanhua; Airhart, Sophia; Liu, Yaxin; Stempien-Otero, April; O’Brien, Kevin D.; Tian, Rong (2020-11-02). "Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure". The Journal of Clinical Investigation. 130 (11): 6054–6063. doi:10.1172/JCI138538. ISSN 0021-9738. PMC 7598081. PMID 32790648.
  15. ^ Tinnevelt, Gerjen H.; Engelke, Udo F. H.; Wevers, Ron A.; Veenhuis, Stefanie; Willemsen, Michel A.; Coene, Karlien L. M.; Kulkarni, Purva; Jansen, Jeroen J. "Variable Selection in Untargeted Metabolomics and the Danger of Sparsity". Metabolites. 10 (11): 470. doi:10.3390/metabo10110470. ISSN 2218-1989. PMC 7698561. PMID 33213095.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  16. ^ Nascimento, Emmani B M; Moonen, Michiel P B; Remie, Carlijn M E; Gariani, Karim; Jörgensen, Johanna A; Schaart, Gert; Hoeks, Joris; Auwerx, Johan; van Marken Lichtenbelt, Wouter D; Schrauwen, Patrick (2021-04-23). "Nicotinamide Riboside Enhances In Vitro Beta-adrenergic Brown Adipose Tissue Activity in Humans". The Journal of Clinical Endocrinology & Metabolism. 106 (5): 1437–1447. doi:10.1210/clinem/dgaa960. ISSN 0021-972X.
  17. ^ Li, Dong-Jie; Sun, Si-Jia; Fu, Jiang-Tao; Ouyang, Shen-Xi; Zhao, Qin-Jie; Su, Li; Ji, Qing-Xi; Sun, Di-Ynag; Zhu, Jia-Hui; Zhang, Guo-Yan; Ma, Jia-Wei; Lan, Xiu-Ting; Zhao, Yi; Tong, Jie; Li, Guo-Qiang (2021-02-25). "NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin". Theranostics. 11 (9): 4381–4402. doi:10.7150/thno.53652. ISSN 1838-7640. PMC 7977447. PMID 33754067.
  18. ^ Altay, Ozlem; Arif, Muhammad; Li, Xiangyu; Yang, Hong; Aydın, Mehtap; Alkurt, Gizem; Kim, Woonghee; Akyol, Dogukan; Zhang, Cheng; Dinler‐Doganay, Gizem; Turkez, Hasan; Shoaie, Saeed; Nielsen, Jens; Borén, Jan; Olmuscelik, Oktay. "Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19". Advanced Science. 8 (17): 2101222. doi:10.1002/advs.202101222. ISSN 2198-3844. PMC 8420376. PMID 34180141.
  19. ^ Stocks, Ben; Ashcroft, Stephen P.; Joanisse, Sophie; Dansereau, Linda C.; Koay, Yen Chin; Elhassan, Yasir S.; Lavery, Gareth G.; Quek, Lake‐Ee; O'Sullivan, John F.; Philp, Ashleigh M.; Wallis, Gareth A.; Philp, Andrew. "Nicotinamide riboside supplementation does not alter whole‐body or skeletal muscle metabolic responses to a single bout of endurance exercise". The Journal of Physiology. 599 (5): 1513–1531. doi:10.1113/JP280825. ISSN 0022-3751.
  20. ^ Veenhuis, Stefanie J.G.; Os, Nienke J.H.; Janssen, Anjo J.W.M.; Gerven, Marjo H.J.C.; Coene, Karlien L.M.; Engelke, Udo. F.H.; Wevers, Ron A.; Tinnevelt, Gerjen H.; Heine, Rob; Warrenburg, Bart P.C.; Weemaes, Corry M.R.; Roeleveld, Nel; Willemsen, Michèl A.A.P. "Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia". Movement Disorders. 36 (12): 2951–2957. doi:10.1002/mds.28788. ISSN 0885-3185. PMC 9291897. PMID 34515380.
  21. ^ a b Zeybel, Mujdat; Altay, Ozlem; Arif, Muhammad; Li, Xiangyu; Yang, Hong; Fredolini, Claudia; Akyildiz, Murat; Saglam, Burcin; Gonenli, Mehmet Gokhan; Ural, Dilek; Kim, Woonghee; Schwenk, Jochen M; Zhang, Cheng; Shoaie, Saeed; Nielsen, Jens. "Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients". Molecular Systems Biology. 17 (10). doi:10.15252/msb.202110459. ISSN 1744-4292. PMC 8724764. PMID 34694070.
  22. ^ a b Wu, Jing; Singh, Komudi; Lin, Amy; Meadows, Allison M.; Wu, Kaiyuan; Shing, Vivian; Bley, Maximilian; Hassanzadeh, Shahin; Huffstutler, Rebecca D.; Schmidt, Mark S.; Blanco, Luz P.; Tian, Rong; Brenner, Charles; Pirooznia, Mehdi; Kaplan, Mariana J. (2022-03-01). "Boosting NAD+ blunts TLR4-induced type I IFN in control and systemic lupus erythematosus monocytes". The Journal of Clinical Investigation. 132 (5). doi:10.1172/JCI139828. ISSN 0021-9738. PMC 8884917. PMID 35025762.
  23. ^ Brakedal, Brage; Dölle, Christian; Riemer, Frank; Ma, Yilong; Nido, Gonzalo S.; Skeie, Geir Olve; Craven, Alexander R.; Schwarzlmüller, Thomas; Brekke, Njål; Diab, Joseph; Sverkeli, Lars; Skjeie, Vivian; Varhaug, Kristin; Tysnes, Ole-Bjørn; Peng, Shichun (2022-03-01). "The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease". Cell Metabolism. 34 (3): 396–407.e6. doi:10.1016/j.cmet.2022.02.001. ISSN 1550-4131. PMID 35235774.
  24. ^ a b Wang, Dennis D.; Airhart, Sophia E.; Zhou, Bo; Shireman, Laura M.; Jiang, Siyi; Melendez Rodriguez, Carolina; Kirkpatrick, James N.; Shen, Danny D.; Tian, Rong; O’Brien, Kevin D. (2022-12-01). "Safety and Tolerability of Nicotinamide Riboside in Heart Failure with Reduced Ejection Fraction". JACC: Basic to Translational Science. 7 (12): 1183–1196. doi:10.1016/j.jacbts.2022.06.012. ISSN 2452-302X. PMC 9831861. PMID 36644285.
  25. ^ Vreones, Michael; Mustapic, Maja; Moaddel, Ruin; Pucha, Krishna A.; Lovett, Jacqueline; Seals, Douglas R.; Kapogiannis, Dimitrios; Martens, Christopher R. "Oral nicotinamide riboside raises NAD + and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin". Aging Cell. 22 (1). doi:10.1111/acel.13754. ISSN 1474-9718. PMC 9835564. PMID 36515353.
  26. ^ Lapatto, Helena A.K.; Kuusela, Minna; Heikkinen, Aino; Muniandy, Maheswary; van der Kolk, Birgitta W.; Gopalakrishnan, Swetha; Pöllänen, Noora; Sandvik, Martin; Schmidt, Mark S.; Heinonen, Sini; Saari, Sina; Kuula, Juho; Hakkarainen, Antti; Tampio, Janne; Saarinen, Tuure (2023-01-13). "Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study". Science Advances. 9 (2): eadd5163. doi:10.1126/sciadv.add5163. ISSN 2375-2548. PMC 9839336. PMID 36638183.
  27. ^ Yulug, Burak; Altay, Ozlem; Li, Xiangyu; Hanoglu, Lutfu; Cankaya, Seyda; Lam, Simon; Velioglu, Halil Aziz; Yang, Hong; Coskun, Ebru; Idil, Ezgi; Nogaylar, Rahim; Ozsimsek, Ahmet; Bayram, Cemil; Bolat, Ismail; Oner, Sena (2023-01-26). "Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial". Translational Neurodegeneration. 12 (1): 4. doi:10.1186/s40035-023-00336-2. ISSN 2047-9158. PMC 9879258. PMID 36703196.{{cite journal}}: CS1 maint: unflagged free DOI (link)
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=ChromaDex&oldid=1141730841"